SCHEMBL6497000

SCHEMBL6497000

Cc1cccnc1C(N)=S

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
RAB9A P51151 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 2/20 0.50
PLAU P00749 1/20 0.50
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50
NOS2 P35228 1/20 0.50
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX12 P18054 1/20 0.38
CTH P32929 1/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
PKM P14618 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
CYP2A6 P11509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8883350 0.83 RAB9A (0.50) MAPTL3MBTL1RAB9AKDM4ENPC1
SCHEMBL29078757 0.81 MAPT (0.47) MAPTL3MBTL1RAB9AKDM4ENPC1
SCHEMBL162188 0.81 L3MBTL1 (0.50) MAPTL3MBTL1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL10515338 0.81 RAB9A (0.48) MAPTL3MBTL1RAB9AKDM4ENPC1
SCHEMBL2240052 0.81 NOS3 (0.54) MAPTL3MBTL1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL17893831 0.79 NOS3 (0.52) MAPTL3MBTL1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL6385939 0.79 L3MBTL1 (0.49) MAPTL3MBTL1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL28847816 0.79 L3MBTL1 (0.49) MAPTL3MBTL1RAB9AKDM4ENPC1
SCHEMBL22725591 0.79 PLAU (0.47) MAPTL3MBTL1RAB9AKDM4ENPC1
SCHEMBL5263024 0.78 PLAU (0.50) MAPTL3MBTL1RAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210062353-A1 LEVELING AGENT AND COPPER PLATING COMPOSITION COMPRISING THE SAME SOULBRAIN CO., LTD. (KR) 2021-03-04 US disclosed
US-20190161877-A1 LEVELING AGENT AND COPPER PLATING COMPOSITION COMPRISING THE SAME SOULBRAIN CO., LTD. (KR) 2019-05-30 US disclosed
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-6884821-B1 Carboxylic acid derivatives and drugs containing the same EISAI CO., LTD. (JP) 2005-04-26 US disclosed
EP-1216980-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI MAPT 4033/4885L3MBTL1 2920/4885RAB9A 2990/4885
US-20190161877-A1 LEVELING AGENT AND COPPER PLATING COMPOSITION COMPRISING THE SAME TET2, DPM1, SUCLG1 MAPT 1663/4885L3MBTL1 1087/4885RAB9A 2405/4885
US-20210062353-A1 LEVELING AGENT AND COPPER PLATING COMPOSITION COMPRISING THE SAME TPMT, TTC14, NACA MAPT 1524/4885L3MBTL1 1128/4885RAB9A 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.